BIOGNOSYS
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers . The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1 .
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer . The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “ Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/ .
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com .
1 Funding reference number FKZ 13GW0451A+B
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 202515.9.2025 09:15:00 CEST | Press release
The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark review.New Dexcom CGM data revealed at the conference will demonstrate how exercise before versus after meals can optimize glucose excursions in pregnant women with Type 1 diabetes.1 Additional findings will demonstrate how CGM can reduce neonatal complications linked to gestational diabetes more effectively than fingersticks.2Data presented at Dexcom’s symposium will reinforce that Dexcom CGM use reduced acute diabetes events.3 DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. This press release features multimedia. Vi
Dotfile Launches Autonomy: Self-Decisioning AI Agent for KYB Compliance15.9.2025 09:00:00 CEST | Press release
Breakthrough technology delivers fully autonomous compliance reviews, achieving up to 94% false positive elimination and speeding up processing by 3x. Dotfile, Europe’s leading AI‑powered compliance operating system, today announced Dotfile Autonomy, the industry‑first fully autonomous AI platform for Know Your Business (KYB) case review. Autonomy enables fintechs and financial institutions to fully automate routine KYB/AML workflows while maintaining regulatory oversight and end‑to‑end auditability. Self-Decisioning Technology Dotfile Autonomy debuts a sophisticated multi-agent AI architecture, combining a central orchestrator with specialized review agents. The system automatically analyzes cases, determines automation levels, and processes routine compliance reviews without the need for human intervention, escalating only complex cases to human reviewers. Vasco Alexandre, Cofounder and CEO of Dotfile, commented: “Our approach delivers huge efficiency gains, while keeping humans in t
Komoot Unveils Modern Design as Part of Ambitious Product Roadmap15.9.2025 09:00:00 CEST | Press release
Komoot, the leading outdoor app, is rolling out a fresh new design: The experience is currently live for Web users worldwide, with Mobile slated for release by the end of September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915468295/en/ The updated design—the first in a series of major initiatives outlined within komoot’s ambitious new roadmap—introduces a refreshed look and includes significant improvements to the user journey to deliver a more intuitive and enjoyable experience overall. At the same time, komoot’s core navigation and workflows remain the same: The result is a modern, intuitive design that still feels familiar to returning users. The most notable changes include: A contemporary design. The new look introduces several refreshed design elements—such as color palette, fonts, icons, and illustrations—to elevate and modernize the overall komoot brand and user experience. A clearer and more intuitive stru
Cardo AI Powers Multitude Bank’s Asset-Based Lending15.9.2025 08:21:00 CEST | Press release
Cardo AI, a leading technology platform for asset-based finance and private credit, today announced a strategic partnership with Multitude Bank p.l.c., a subsidiary of the listed Multitude AG. The collaboration will use Cardo AI’s platform to automate and streamline Multitude Bank’s asset-based lending (ABL) operations, enhancing efficiency and transparency in funding for small and medium-sized enterprises (SMEs). “Technology is the key to accelerating growth in asset-based credit,” said Altin Kadareja, Co-Founder & CEO of Cardo AI. “By automating and streamlining critical operations, our platform helps institutions like Multitude enhance the efficiency of their ABL businesses and provide faster, more flexible funding solutions to SMEs.” “Our clients expect both speed and reliability,” said Alain Nydegger, CEO of Wholesale Banking at Multitude Group. “By working with innovative technology partners, we can scale our asset-based lending operations more efficiently. Consolidating our ABL
Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-0115.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) reports revenues of CHF 5.2m for H1 2025, a like for like yoy growth of 14% vs 6 months of revenues of Curatis AG in 2024. In addition, Curatis was able to sign a significant partnership with Phoenix Labs, Ireland, adding 4 products that generated approximately CHF 5m of revenues in 2024. The loss for the period amounted to CHF -1.2m, mainly driven by increased development expenses for C-PTBE-01 (corticorelin). Cash flow amounted to CHF -1.0m. As planned, Curatis held a Type B meeting with the US Food and Drug Administration (FDA) on 9 September 2025. Business development and finances Product sales in the first half of the year amounted to CHF 5.0m and services revenues to CHF 0.2m. Curatis AG was able to increase the sales of its distribution business from CHF 4.6m (H1 2024) to CHF 5.2m (H1 2025) in the entire 6 months due to strong organic growth of the existing portfolio and new products, which corresponds to a growth of 14%. The loss for the period amo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom